Teva Pharmaceutical Industries stock closed at $30.81 on July 24, sitting below key moving averages. Wall Street analysts project over 60% upside with a 100% buy rating. The daily chart, however, is not confirming that optimism. The gap between bullish narratives and technical weakness defines TEVA’s current tension.

Key takeaways

• TEVA closed at $30.81 on July 24, below the daily EMA20 at $32.17 and EMA50 at $32.81
• The EMA200 at $29.94 serves as the critical structural floor that must hold for any recovery
• Daily RSI at 40.15 reflects weak momentum, while the MACD confirms persistent downward pressure
• Wall Street analysts maintain a 100% buy rating with price targets…